Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

323 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.
Rubinstein PG, Moore PC, Bimali M, Lee JY, Rudek MA, Chadburn A, Ratner L, Henry DH, Cesarman E, DeMarco CE, Costagliola D, Taoufik Y, Ramos JC, Sharon E, Reid EG, Ambinder RF, Mitsuyasu R, Mounier N, Besson C, Noy A; AIDS Malignancy Consortium; Lymphoma Study Association. Rubinstein PG, et al. Among authors: ambinder rf. Lancet Haematol. 2023 Aug;10(8):e624-e632. doi: 10.1016/S2352-3026(23)00157-6. Lancet Haematol. 2023. PMID: 37532416 Clinical Trial.
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study.
Rajdev L, Jackie Wang CC, Joshi H, Lensing S, Lee J, Ramos JC, Baiocchi R, Ratner L, Rubinstein PG, Ambinder R, Henry D, Streicher H, Little RF, Chiao E, Dittmer DP, Einstein MH, Cesarman E, Mitsuyasu R, Sparano JA; AIDS Malignancy Consortium. Rajdev L, et al. Among authors: ambinder r. Cancer. 2024 Mar 15;130(6):985-994. doi: 10.1002/cncr.35110. Epub 2023 Nov 14. Cancer. 2024. PMID: 37962072
Sir Michael Anthony Epstein (1921-2024).
Ambinder RF, Xian RR. Ambinder RF, et al. Science. 2024 Apr 19;384(6693):274. doi: 10.1126/science.adp2961. Epub 2024 Apr 18. Science. 2024. PMID: 38635698
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years.
Webster JA, Reed M, Tsai HL, Ambinder A, Jain T, Dezern AE, Levis MJ, Showel MM, Prince GT, Hourigan CS, Gladstone DE, Bolanos-Meade J, Gondek LP, Ghiaur G, Dalton WB, Paul S, Fuchs EJ, Gocke CB, Ali SA, Huff CA, Borrello IM, Swinnen L, Wagner-Johnston N, Ambinder RF, Luznik L, Gojo I, Smith BD, Varadhan R, Jones RJ, Imus PH. Webster JA, et al. Among authors: ambinder rf. Transplant Cell Ther. 2023 Mar;29(3):182.e1-182.e8. doi: 10.1016/j.jtct.2022.12.018. Epub 2022 Dec 29. Transplant Cell Ther. 2023. PMID: 36587740 Free PMC article.
Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087).
Haigentz M Jr, Lee JY, Chiao EY, Aboulafia DM, Ratner L, Ambinder RF, Baiocchi RA, Mitsuyasu RT, Wachsman W, Sparano JA, Rudek MA. Haigentz M Jr, et al. Among authors: ambinder rf. Clin Cancer Res. 2023 Dec 15;29(24):5038-5046. doi: 10.1158/1078-0432.CCR-23-1142. Clin Cancer Res. 2023. PMID: 37523145 Clinical Trial.
323 results